Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:41:43.801Z.
Calculation as of: 2026-10-06T15:41:43.801Z.
Quote observation: 2026-10-06T15:39:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ec04a23f2eccb1c46d806cafb3c6508f31619b4012dc27c85b71ebd533873098
PE RATIO
N/A
Market Cap
$1.46M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46M
PE Ratio
N/A
TTM Avg
21295.08
3Y Avg
21295.08
5Y Avg
21295.08
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | $1.46M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.46M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.46M | N/A | 21295.08 | 21295.08 | 21295.08 |
| Curis, Inc. (CRIS)vs › | $1.48M | N/A | 47.01 | 47.01 | 34.74 |
| NEXGEL, Inc. (NXGL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.20M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.17M | N/A | 0.03 | 0.03 | 0.03 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
